Multicentric Papillary Thyroid Carcinoma: Stratification for TreatmentSalvador J. Diaz-Cano*
Department of Histopathology, King’s College Hospital and King’s Health Partners, London, United Kingdom
- *Corresponding Author:
- Salvador J. Diaz-Cano
King’s College Hospital
Dept of Histopathology
Denmark Hill, London, Greater London
SE5 9RS, United Kingdom
Tel: +44 20 3299-3041
Fax: +44 20 3299-3670
E-mail: [email protected]
Received date: December 18, 2013; Accepted date: March 29, 2014; Published date: March 31, 2014
Citation: Diaz-Cano SJ (2014) Multicentric Papillary Thyroid Carcinoma: Stratification for Treatment. J Cytol Histol 5:238. doi:10.4172/2157-7099.1000238
Copyright: © 2014 Diaz-Cano SJ. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Tumor stage is the main prognosticator of differentiated thyroid carcinomas, but it needs further stratification for multicentric neoplasms (most frequently papillary thyroid carcinomas, PTC), which frequently present as foci smaller than 1cm and are considered by default as high-risk tumors. Not all cases of multicentric PTC should be considered of high risk and they should be stratified to avoid unnecessary radioiodine ablation in selected cases. Currently, there are known variables for this stratification: size and number of tumor foci, clonal patterns, and specific markers of aggressive behaviour (infiltrative growth, BRAF mutation). In a near future, the identification of a gene expression pattern associated with a higher risk of recurrence would allow us to focus more aggressive treatment appropriately.